- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00837174
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT)
Phase II Study of Combination Vorinostat and Bortezomib in Patients With Relapsed and/or Refractory Non-Hodgkin Lymphoma
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
More selective and less toxic therapeutic strategies are needed to improve cure rates and prolong survival in patients with relapsed and/or refractory non-Hodgkin Lymphoma.
Amongst the multiple new pathways recently studied two have emerged as potentially important targets for new agents in lymphoma. These include the ubiquitin proteasome pathway and the biochemical reactions that control histone acetylation. The first two agents in each class to have been studied in lymphomas are: bortezomib and vorinostat. Bortezomib has been granted FDA approval for the treatment of mantle cell lymphoma and has established activity in a variety of B-cell lymphomas including follicular, marginal zone and diffuse large B-cell lymphoma. Vorinostat or SAHA (suberoylanilide hydroxamic acid) has been FDA approved for the treatment of refractory cutaneous T-cell lymphomas and has also shown activity in other lymphomas.
Synergistic activity between vorinostat and bortezomib has been observed in different cell lines. The proposed study will be a phase II trial of the combination of vorinostat and bortezomib at the recommended dose-schedule in patients with recurrent and/or refractory lymphomas, indolent and aggressive, and B or T.
Tipo de estudio
Fase
- Fase 2
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically confirmed non-Hodgkin Lymphoma including small lymphocytic lymphoma, lymphoplasmacytic lymphoma, follicular center cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, nasal NK/T cell lymphoma, mycosis fungoides/Sezary syndrome, angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified
- Received 2 or > prior therapies, which may include hematopoietic cell transplant (HCT)
- Received treatment with a nucleoside analog, or an alkylating agent, an anthracycline and/or in the case of B cell lymphomas, rituximab
- Resistant disease to 2 regimens or resistant disease to at least 1 regimen after first relapse
Bi-dimensionally measurable disease documented within 30 days prior to enrollment. Bidimensionally measurable disease is defined as:
- A lymph node or tumor mass that can be accurately measured in two dimensions by CT,MRI, medical photograph (skin or oral lesion), plain X-ray, PET scan or other conventional technique and a greatest diameter of 1 cm or >; or palpable lesions with both diameters > 2 cm (lesion measured in 2 largest perpendicular dimensions in millimeters)
- For the purposes of this protocol, disease should be located in an area of no prior radiation therapy or a clear progression in an area that was previously irradiated
Adequate organ and marrow function obtained < or = to 14 days prior to enrollment as defined by a(n):
- ANC > or = to 1,000/microliter
- Platelet count > or = to 100,000/microliter, or > or = to 75,000/microliter if the bone marrow is involved
- Hemoglobin level > or = to 9 g/dL
- Total bilirubin < or = to 1.5 x institutional upper limit of normality (ULN).(If abnormal, direct bilirubin less than or equal to 1.5 x institutional ULN)
- ALT or AST < or = to 2.5 x institutional ULN (< or = to 5 x institutional ULN if liver involvement with lymphoma)
- Serum creatinine < or = to 1.5 x institutional ULN
- Zubrod (ECOG) Performance Status of 0 or 1
- Age > than or = to 18 years
- Life expectancy > or = to 3 months as clinically determined by referring physician
- Female patient is either post menopausal, free from menses for > 2 years, surgically sterilized or willing to use highly effective methods of contraception (i.e., a condom in conjunction with a diaphragm, or spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence ) to prevent pregnancy throughout the study, starting with visit 1
- Female patients of childbearing potential must have a negative serum pregnancy test (beta-HCG) within 72 hours of enrollment and should not be nursing due to the potential for congenital abnormalities and of harm to nursing infants due to this treatment regimen
- Male patient agrees to use an adequate method of contraception (i.e., a condom if female partner uses a diaphragm, spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence) for the duration of the study and for 12 weeks after the last dose
- Patient must be able to swallow capsules
- Signed and dated IRB/ethics committee-approved informed consent before any protocol specific screening procedures are performed
- Both men and women of all races and ethnic groups are eligible for this trial
Exclusion Criteria:
- Prior investigational therapy within 3 weeks of enrollment. Investigational therapy is defined as treatment that is not approved for any indication
- CNS metastases, as indicated by clinical symptoms,cerebral edema, requirement for corticosteroids and/or progressive growth (treated CNS metastases must be stable for greater than 2 weeks prior to enrollment)
- Active second malignancy that requires treatment or that would interfere with assessment of response
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer with < 5 years of documented disease-free status
Treatment with the following within the timeframe specified prior to enrollment:
- Chemotherapy, radiotherapy, immunotherapy (active (such as vaccines) or passive (such as monoclonal antibodies or immunotoxins)) or major surgery < or = to 3 weeks;
- Nitrosourea, or mitomycin < or = to 6 weeks
- Radioimmunotherapy (e.g. Bexxar or Zevalin) < or = to 12 weeks
- Concurrent enzyme-inducing anticonvulsant agents or valproic acid in last 4 weeks
- Prior bortezomib or any other proteasome inhibitor
- Prior vorinostat or any other histone deacetylase inhibitor
- Concurrent systemic corticosteroids (<10 mg/day of prednisone or equivalent for adrenal insufficiency or acute allergic reactions allowed)
Uncontrolled current illness including, but not limited to:
- Clinically or laboratory determined active infection
- Clinically limiting congestive heart failure or ejection fraction (EF) <45%
- Clinically unstable angina pectoris (or myocardial infarction within 6 months of Day 1)
- Clinically significant cardiac arrhythmia
- Limiting pulmonary hypertension
- Pre-existing neuropathy ≥ grade 2
- Patients with pleural effusions, ascites or peripheral edema grade 2 or >
- HIV
- Active viral hepatitis
- Major surgery or significant traumatic injury within 21 days prior to enrollment (this does not apply to placement of a venous access device)
- Hypersensitivity to any of the components in vorinostat or bortezomib or agents containing boron or mannitol
- Significant psychiatric illness/social situations that would limit compliance with study medication and requirements of the study as determined by study MD
- Significant medical illness or abnormal laboratory finding that would, in the investigator's judgment, increase the subject's risk by participating in this study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Combination Vorinostat + Bortezomib
Six cycle combination therapy with vorinostat and bortezomib.
|
Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Determine the response rate of this regimen in this patient population.
Periodo de tiempo: 6 cycles
|
6 cycles
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Determine the progression free survival of this regimen in this patient population.
Periodo de tiempo: entire length of study
|
entire length of study
|
Determine the safety and tolerability of this regimen in this patient population.
Periodo de tiempo: throughout course of study
|
throughout course of study
|
To correlate response rate and progression free survival with pre-treatment and post-treatment NFkB, TRAIL, cyclin D1, histone acetylation, EBV related proteins, and CTA expression.
Periodo de tiempo: 6 cycles
|
6 cycles
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Hector A Preti, M.D., The Methodist Hospital Research Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Linfoma difuso de células B grandes
- Linfoma de células B
- Linfoma de Burkitt
- linfoma de células del manto
- linfoma de la zona marginal
- linfoma de células T periféricas
- micosis fungoide
- linfoma de linfocitos pequeños
- linfoma linfoblástico
- no linfoma de Hodgkin
- linfoma agresivo
- linfoma indolente
- Linfoma de células T
- linfoma linfoplasmocitario
- anaplastic large B cell lymphoma
- transformed follicular center cell lymphoma
- transformed marginal zone lymphoma
- transformed small lymphocytic lymphoma
- grade 3 follicular center cell lymphoma
- blastic form marginal zone lymphoma
- transformed cutaneous T cell lymphoma
- mycosis fungoides stage IV
- angioimmunoblastic lymphadenopathy-like T-cell lymphoma
- nasal NK/T cell lymphoma
- follicular center cell lymphoma grade 1
- follicular center cell lymphoma grade 2
Términos MeSH relevantes adicionales
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Neoplasias
- Trastornos linfoproliferativos
- Enfermedades linfáticas
- Trastornos inmunoproliferativos
- Linfoma
- Linfoma No Hodgkin
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Inhibidores de histona desacetilasa
- Bortezomib
- Vorinostat
Otros números de identificación del estudio
- Pro00002085
- 0908-0284 (Otro identificador: Houston Methodist Research Institute IRB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre No linfoma de Hodgkin
-
Rutgers, The State University of New JerseyTerminadoMBSR-STEM | PMR-STEM | MBSR-NON-STEM | PMR - SIN VÁSTAGOEstados Unidos
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminadoLinfoma de Hodgkin recurrente | Linfoma de Hodgkin refractario | Linfoma no Hodgkin de células B refractario | Linfoma no Hodgkin de células T refractario | Linfoma no Hodgkin de células B recurrente | Linfoma no Hodgkin de células T recurrenteEstados Unidos
-
National Cancer Institute (NCI)TerminadoLinfoma de Hodgkin en adultos recidivante | Linfoma de Hodgkin en adultos en estadio III | Linfoma de Hodgkin en adultos en estadio IV | Linfoma de Hodgkin infantil recidivante/refractario | Linfoma de Hodgkin infantil en estadio III | Linfoma de Hodgkin infantil en estadio IV | Linfoma de Hodgkin... y otras condicionesEstados Unidos
-
University of WashingtonReclutamientoLinfoma de Hodgkin recurrente | Linfoma de Hodgkin refractario | Linfoma no Hodgkin recurrente | Linfoma no Hodgkin refractarioEstados Unidos
-
Tomsk National Research Medical Center of the Russian...Uppsala UniversityTerminadoLinfoma de Hodgkin en adultos | Linfoma no Hodgkin en adultosFederación Rusa
-
Marker Therapeutics, Inc.ReclutamientoNo linfoma de Hodgkin | Linfoma no Hodgkin en adultos | Linfoma no Hodgkin, refractario | Linfoma no Hodgkin en recaídaEstados Unidos
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Activo, no reclutandoLinfoma de Hodgkin en estadio III de Ann Arbor | Linfoma de Hodgkin en estadio IIIA de Ann Arbor | Linfoma de Hodgkin en estadio IIIB de Ann Arbor | Linfoma de Hodgkin en estadio IV de Ann Arbor | Linfoma de Hodgkin en estadio IVA de Ann Arbor | Linfoma de Hodgkin en estadio IVB de Ann Arbor | Linfoma... y otras condicionesEstados Unidos
-
Tessa TherapeuticsActivo, no reclutandoLinfoma de Hodgkin en adultos | Enfermedad de Hodgkin Recurrente | Enfermedad de Hodgkin refractario | Enfermedad de Hodgkin, PediátricaEstados Unidos
-
Shanghai Zhongshan HospitalReclutamientoLinfoma | Linfoma de Hodgkin | No linfoma de HodgkinPorcelana
-
GenmabReclutamientoNo linfoma de Hodgkin | Linfoma de Hodgkin clásicoEstados Unidos, Australia
Ensayos clínicos sobre Vorinostat in combination with Bortezomib
-
Hamid SayarBayer; Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.Terminado
-
Merck Sharp & Dohme LLCTerminado
-
University of Wisconsin, MadisonMerck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.TerminadoCarcinoma De Pulmón De Células No Pequeñas
-
European Organisation for Research and Treatment...Retirado
-
Masonic Cancer Center, University of MinnesotaMerck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.TerminadoLeucemia | Síndrome mielodisplásicoEstados Unidos
-
National Cancer Institute (NCI)TerminadoSarcoma | Linfoma | Neuroblastoma | Tumor de WilmsEstados Unidos
-
University of LeedsMerck Sharp & Dohme LLC; Myeloma UKTerminadoMieloma múltipleReino Unido
-
University of VirginiaTerminadoCáncer de pulmón de células no pequeñasEstados Unidos
-
National Cancer Institute (NCI)TerminadoTumor sólido adulto no especificado, protocolo específicoEstados Unidos
-
National Cancer Institute (NCI)TerminadoSarcoma de tejido blando en adultos recidivante | Sarcoma de tejido blando en adultos en estadio III | Sarcoma de tejido blando en adultos en estadio IVEstados Unidos